<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802292</url>
  </required_header>
  <id_info>
    <org_study_id>NBI(CT)-YQ23-2015-001</org_study_id>
    <nct_id>NCT03802292</nct_id>
  </id_info>
  <brief_title>First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23</brief_title>
  <official_title>First-In-Man, Phase I, Single-Blind, Placebo-Controlled, Ascending Single Dose Study of Intravenous YQ23 in Healthy Male and Female Subjects to Assess Safety, Tolerability, and Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Beta Innovation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New Beta Innovation Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to test the safety, tolerability, pharmacokinetics (PK-the amount of study drug
      in the blood), and immunogenicity (how the study drug affects the immune system) of single
      dose and dose levels of an investigational drug called YQ23.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-man, phase 1, single-blind, randomized, placebo-controlled study in
      healthy volunteers. It will be conducted at a single centre and will enroll approximately 64
      subjects. Subjects will either receive a single dose of study drug or placebo in a 3:1 ratio.
      Eight dose levels of YQ23 will be evaluated.

      Each dose level group will be divided into 2 cohorts, with each cohort being dosed at last 24
      hours apart. The leading cohort will comprise of 2 subjects, with 1 subject receiving YQ23
      and 1 subject receiving placebo. The remaining cohort will comprise of 6 subjects, with 5
      receiving YQ23 and 1 receiving placebo.

      Safety assessments will be performed throughout the dosing and follow-up periods, and
      multiple PK samples will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2019</start_date>
  <completion_date type="Anticipated">January 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation study to determine the safe dose level.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by the incidence of Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>From the time of signing the Informed Consent Form to final discharge from the study (approximately 8 weeks)</time_frame>
    <description>Number of TEAEs will be listed according to the severity (mild, moderate, severe) as assessed by the Investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by the incidence of laboratory abnormalities, based on haematology, clinical chemistry, and urinalysis test results</measure>
    <time_frame>From the time of signing the Informed Consent Form to D8 visit (approximately 36 days)</time_frame>
    <description>All serum biochemistry, haematology, and urinalysis data outside the clinical reference ranges will be listed by parameter and treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by 12-lead electrocardiogram (ECG)</measure>
    <time_frame>From the time of signing the Informed Consent Form to D8 visit (approximately 36 days)</time_frame>
    <description>ECG parameters such as PR, QRS, QT and QTcF in milliseconds will be recorded. Clinically significant abdominal findings will be reported as Adverse Events (AE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by echocardiogram</measure>
    <time_frame>From the time of signing the Informed Consent Form to D2 visit (approximately 30 days)</time_frame>
    <description>Clinically significant abnormal echocardiogram findings will be recorded as AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by vital sign measurement of blood pressure</measure>
    <time_frame>From From the time of signing the Informed Consent Form to D8 visit (approximately 36 days)</time_frame>
    <description>Systolic and Diastolic blood pressure (in mmHg) which is outside the clinical reference ranges and considered as clinically significant will be reported as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by vital sign measurement of pulse rate</measure>
    <time_frame>From From the time of signing the Informed Consent Form to D8 visit (approximately 36 days)</time_frame>
    <description>Pulse rate (in beats/min) which is outside the clinical reference ranges and considered as clinically significant will be reported as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by vital sign measurement of oral body temperature</measure>
    <time_frame>From From the time of signing the Informed Consent Form to D8 visit (approximately 36 days)</time_frame>
    <description>Body temperature (in degree Celsius) which is outside the clinical reference ranges and considered as clinically significant will be reported as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by local tolerability assessment: pain</measure>
    <time_frame>From the time before dosing to D3 post dose (3 days)</time_frame>
    <description>The intravenous (IV) infusion site will be assessed for pain according to the following scale [Grade 0=none, 1=does not interfere with activity, 2=interferes with activity or requires repeated use of non-narcotic pain medication, 3=prevent daily activity or requires repeated use of narcotic pain medication, 4=requires medical intervention greater than analgesia]. Grade 3 or above will be recorded as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by local tolerability assessment: edema</measure>
    <time_frame>From the time before dosing to D3 post dose (3 days)</time_frame>
    <description>The intravenous (IV) infusion site will be assessed for edema according to the following scale [Grade 0=0 to 24mm, 1=25 to 50mm and not interfere with activity, 2=51 to 100mm, or interferes with activity, 3=more than 100mm, and interferes with daily activity, 4=necrosis]. Grade 3 or above will be recorded as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by local tolerability assessment: erythema intensity</measure>
    <time_frame>From the time before dosing to D3 post dose (3 days)</time_frame>
    <description>The intravenous (IV) infusion site will be assessed for erythema intensity according to the following scale [Grade 0=None, 1=light pink, 2=pinkish red, 3=intense red]. Grade 3 or above will be recorded as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by local tolerability assessment: erythema size</measure>
    <time_frame>From the time before dosing to D3 post dose (3 days)</time_frame>
    <description>The intravenous (IV) infusion site will be assessed for erythema size according to the following scale [Grade 0=0 to 24mm, 1=25 to 50mm, 2=51 to 100mm, 3=more than 100mm, 4=necrosis or exfoliative dermatitis]. Grade 3 or above will be recorded as AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of YQ23 as assessed by Area under curve (AUC) on all subjects</measure>
    <time_frame>From study Day 1 (dosing of study drug) until Day 4 of trial participation.</time_frame>
    <description>Plasma levels of YQ23 will be serially evaluated following dosing of study drug, and the AUC will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of YQ23 as assessed by the maximum concentration of YQ23 on all subjects</measure>
    <time_frame>From study Day 1 (dosing of study drug) until Day 4 of trial participation.</time_frame>
    <description>Plasma levels of YQ23 will be serially evaluated following dosing of study drug, and the maximum plasma concentration (Cmax) will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose YQ23</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>YQ23</intervention_name>
    <description>Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated</description>
    <arm_group_label>Single Ascending Dose YQ23</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Single dose of the matching placebo delivered via intravenous route.</description>
    <arm_group_label>Single Dose Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, of any ethnic origin, between 18 and 50 years of age, inclusive.

          -  Body mass index between 18.0 and 30.0 kg/m2, inclusive, and body weight between 50 and
             100 kg, inclusive.

          -  In good health, determined by no clinically significant findings from medical history,
             physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory
             evaluations (congenital non-hemolytic hyperbilirubinemia [eg, suspicion of Gilbert's
             syndrome based on total and direct bilirubin] is not acceptable) at Screening and
             Check in, as assessed by the Investigator (or designee).

          -  Females of non-childbearing potential defined as permanently sterile (ie, due to
             hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal
             (defined as at least 12 months postcessation of menses without an alternative medical
             cause and follicle stimulating hormone level â‰¥ 40 mIU/mL). Females will not be
             pregnant or lactating, and females of childbearing potential and males will agree to
             use contraception as detailed in the protocol.

          -  Able to comprehend and willing to sign an Informed Consent Form and to abide by the
             study restrictions.

          -  Subjects must agree to receive a bovine product.

        Exclusion Criteria:

          -  Significant history or clinical manifestation of any metabolic, allergic,
             dermatological, hepatic, renal, haematological, pulmonary, cardiovascular,
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as
             determined by the Investigator (or designee).

          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance (excluding non-active hay fever), unless approved by the
             Investigator (or designee).

          -  Any abnormality in the 12-lead ECG that, in the opinion of the Investigator (or
             designee), increases the risk of participating in the study.

          -  Any clinically relevant findings on echocardiography, including left ventricular
             ejection fraction &lt; 50% at baseline.

          -  Supine blood pressure and supine pulse rate higher than 140/90 mmHg and 100 bpm,
             respectively, or lower than 90/50 mmHg and 40 bpm, respectively, at Screening or
             Check-in, confirmed by a repeat measurement.

          -  Liver function test results for aspartate aminotransferase (AST), alanine
             aminotransferase (ALT), alkaline phosphatase (ALP), and/or bilirubin &gt; 1.5 x Upper
             Limit of Normal (ULN) at Screening or Check-in confirmed by repeat measurement.

          -  Total red blood cell count, total white blood cell count, and/or haemoglobin levels
             outside of the normal reference range at Screening or Check-in, confirmed by repeat
             measurement.

          -  History of alcoholism or drug/chemical abuse within 2 years prior to Check in.

          -  Alcohol consumption of &gt; 21 units per week for males and &gt; 14 units for females.

          -  Positive alcohol breath test result or positive urine drug screen (confirmed by
             repeat) at Screening or Check in.

          -  Positive hepatitis panel and/or positive human immunodeficiency virus test.

          -  Participation in a clinical study involving administration of an investigational drug
             (new chemical entity) in the past 90 days prior to dosing.

          -  Use or intend to use any prescription medications/products other than hormone
             replacement therapy (HRT), oral, implantable, transdermal, injectable, or intrauterine
             contraceptives within 14 days prior to dosing, unless deemed acceptable by the
             Investigator (or designee).

          -  Use or intend to use slow release medications/products considered to still be active
             within 14 days prior to dosing, unless deemed acceptable by the Investigator (or
             designee).

          -  Use or intend to use any non-prescription medications/products (with the exception of
             vitamins/mineral supplements) and phytotherapeutic/herbal/plant derived preparations
             within 7 days prior to dosing, unless deemed acceptable by the Investigator (or
             designee).

          -  Smoke more than 10 cigarettes or use the equivalent tobacco or nicotine containing
             products per day.

          -  Receipt of blood products within 2 months prior to Check in.

          -  Receipt of bovine Haemoglobin-based Oxygen Carrier (HBOC) or other HBOC in the past.

          -  Donation of blood from 3 months prior to Screening, plasma from 7 days prior to
             Screening, or platelets from 6 weeks prior to Screening, or donations on more than 2
             occasions within the 12 months preceding dosing.

          -  Poor peripheral venous access.

          -  Have previously completed or withdrawn from this study.

          -  Have known allergies to bovine products.

          -  Are vegetarians.

          -  Subjects who have had a clinically significant illness as determined by the
             Investigator within 4 weeks of the start of dose administration.

          -  Subjects who, in the opinion of the Investigator (or designee), should not participate
             in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Billy Lau, PhD</last_name>
    <role>Study Director</role>
    <affiliation>New Beta Innovation Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Nam</last_name>
    <phone>+852 2133 5332</phone>
    <email>eric.nam@newbinnovation.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yolanda Yan</last_name>
    <phone>+852 2133 6054</phone>
    <email>yolanda.yan@newbinnovation.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Covance CRU Limited</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 0113 301 3500</phone>
    </contact>
    <investigator>
      <last_name>Jim Bush, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

